Affinity DataKi: 0.120nMAssay Description:Inhibition of binding of [3H]SP to Tachykinin receptor 1 of human tachykinin receptor expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.140nMAssay Description:Inhibition of binding of [3H]SP to Tachykinin receptor 1 of human tachykinin receptor expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.170nMAssay Description:Inhibition of binding of [3H]SP to Tachykinin receptor 1 of human tachykinin receptor expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.270nMAssay Description:Inhibition of binding of [3H]SP to Tachykinin receptor 1 of human tachykinin receptor expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 0.340nMAssay Description:Inhibition of binding of [3H]NKA to human Tachykinin receptor 2 (NK2) in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 0.640nMAssay Description:Inhibition of binding of [3H]NKA to human Tachykinin receptor 2 (NK2) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.900nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 0.920nMAssay Description:Inhibition of binding of [3H]NKA to human Tachykinin receptor 2 (NK2) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 9.40nMAssay Description:Inhibition of binding of [125I]MPNI to human Tachykinin receptor 3 (NK3) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 35nMAssay Description:Inhibition of binding of [3H]NKA to human Tachykinin receptor 2 (NK2) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 39nMAssay Description:Inhibition of binding of [125I]MPNI to human Tachykinin receptor 3 (NK3) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 40nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 67nMAssay Description:Inhibition of binding of [3H]NKA to human Tachykinin receptor 2 (NK2) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 74nMAssay Description:Inhibition of binding of [125I]MPNI to human Tachykinin receptor 3 (NK3) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
Affinity DataKi: 75nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 146nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 220nMAssay Description:Inhibition of binding of [125I]MPNI to human Tachykinin receptor 3 (NK3) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 250nMAssay Description:Displacement of [3H]-MPEP from human mGluR5More data for this Ligand-Target Pair
Affinity DataKi: 1.62E+3nMAssay Description:Inhibition of binding of [3H]SP to human Tachykinin receptor 1 expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.37E+3nMAssay Description:Displacement of [3H]-MPEP from human mGluR5More data for this Ligand-Target Pair
Affinity DataKi: 9.19E+3nMAssay Description:Inhibition of binding of [125I]MPNI to human Tachykinin receptor 3 (NK3) expressed in mouse erythroleukemia cellsMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.140nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.430nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Antagonist activity at human kappa opioid receptor assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.520nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.610nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.620nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.620nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.720nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.950nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human kappa opioid receptor assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.5nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.70nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.70nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair